ReviewJournal of cardiothoracic surgery2025
Research progress on macrophages in cardiovascular diseases.
Review in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Macrophage-associated kinase signaling in atherosclerosis - a systematic review.Cell communication and signaling : CCS · 2026Pooled it
- Chronic β-Blockade and Systemic Homeostasis: Molecular Integration of Cardiorenal and Immune Pathways, a Narrative Review.Biomolecules · 2025Review
- Cross-Talk Between Neutrophils and Macrophages Post-Myocardial Infarction: From Inflammatory Drivers to Therapeutic Targets.International journal of molecular sciences · 2025Review
- Senescent Polarization of Macrophages and Inflammatory Biomarkers in Cardiovascular Disease.Cells · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
OBJECTIVE AND
designCardiovascular diseases (CVD) are the leading causes of death worldwide, imposing a great burden on society. In recent years, macrophages have garnered widespread attention in CVD research. Macrophages are an important component of the body's immune system, playing a critical role in clearing pathogens, repairing damaged tissues, and regulating inflammatory responses, have the potential to serve as a potential target for the treatment of CVD. MATERIALS AND
methodsTo make up this review, studies covering Macrophage subtypes and signaling pathways, CVD were selected from the main medical databases.
conclusionIn CVD, macrophages can differentiate into different phenotypes(M1, M2, M4, et al.) according to their microenvironment by their plasticity and heterogeneity, release different cytokines, are regulated by multiple signaling pathways(PI3K/Akt, TLR4, TGF-β/Smads, et al.), and play other functions in CVD. M1 initiates and maintains inflammation by secreting pro-inflammatory factors, and M2 participates in the regression of inflammation and tissue repair by secreting anti-inflammatory factors. Therefore, by regulating the signaling pathway, it reduces the aggregation of macrophages, promotes the polarization of macrophages to M2, or restores M1/M2 homeostasis to improve the inflammatory microenvironment and delay CVD progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.